07/07/2026
A new peer-reviewed case series examines the use of TRAUMAGEL® for hemorrhage control and tourniquet removal in traumatic extremity injuries. Across three clinical cases, TRAUMAGEL helped achieve sustained hemorrhage control and enabled tourniquet removal without rebleeding.
The study was authored by trauma and emergency medicine clinicians from Louisiana State University Health Sciences Center and East Baton Rouge Parish EMS.
Read the full study highlights: https://cresilon.com/2026/07/07/traumagel-study-highlights-sustained-hemorrhage-control-and-tourniquet-removal-without-rebleeding/
Clinical cases demonstrate successful use of TRAUMAGEL during tourniquet conversion in prolonged field care, including in gunshot wounds, industrial trauma and sharp-force injuries NEW YORK (July 7, 2026) — Cresilon Inc. (“Cresilon”), a Brooklyn-based biotechnology company focused on hemostati...